NOVO NORDISK A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 981.7 DKK | +0.12% |
|
+0.04% | +40.72% |
| 02:43pm | Novo Nordisk to present 34 abstracts at ADA | CF |
| 17/06 | Health Care Flat as Traders Wait More Obesity-Drug Updates - Health Care Roundup | DJ |
Presentation Operator MessageOperator (Operator)Good day, and welcome to the Q3 2016 Novo Nord...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
07/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
980.5
DKK
Average target price
934.3
DKK
Spread / Average Target
-4.71%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +40.72% | 63TCr | |
| +52.42% | 80TCr | |
| -6.97% | 35TCr | |
| +17.59% | 32TCr | |
| +10.87% | 30TCr | |
| +17.07% | 24TCr | |
| +0.82% | 22TCr | |
| +5.01% | 16TCr | |
| -5.26% | 15TCr | |
| -1.65% | 12TCr |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Transcript : Novo Nordisk A/S, Q3 2015 Earnings Call, Oct 29, 2015
